MAVIRET (glecaprevir /pibrentasvir), fixed direct-acting antiviral combination

High clinical benefit for the treatment of chronic hepatitis C virus genotypes 1 to 6 and minor clinical added value compared to other previously available direct-acting antiviral combinations

• MAVIRET has been granted a marketing authorisation for the treatment of chronic hepatitis C in adults infected with hepatitis C virus (HCV) genotypes 1 to 6.

• Its pan-genotypic virological efficacy is high, with a treatment duration of 8 to 12 weeks for most patients without cirrhosis or with compensated cirrhosis.

• Its efficacy has been demonstrated in specific populations such as kidney failure or haemodialysis patients for whom the alternatives are limited.

• Its safety and resistance profiles are satisfactory but it has a high medicinal interaction potential.